Equillium Inc at Leerink Partners Global Healthcare Conference Transcript
All right, good morning, everybody. I'm Pasha Sarraf with Leerink and I'm delighted to host Bruce Steel and Steve Connelly from Equillium. Bruce is the President and Chief Business Officer; and Steve is the Chief Scientific Officer. Equillium is a very exciting company and they've just recently had an announcement around their -- the indications that they've chosen.
So, let's get started by first talking about sort of what the announcement was, the indications you're going after and then I'd like to get into the biology.
Okay, excellent. Well, thank you, Pasha, and thank you everybody for attending and hearing a little bit about the Equillium story. We're very pleased to be here today.
So, the announcement that we provided on Tuesday was our first update since our public offering which was completed in October. And we announced primarily two things; one is the addition of lupus nephritis as our next clinical indication that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
